Back to Newsroom
Back to Newsroom

SodaStream Beats on Earnings; Pfizer CEO says Drug Development would accelerate with AstranZeneca Merger

Thursday, 15 May 2014 12:10 AM

Topic:

Pfizer Inc. (NYSE: PFE) - For an in-depth report on Pfizer Inc. follow: www.BullTrends.com/stockquote/PFE

Shares of Pfizer Inc. closed down 0.34% on about 26.7 million shares traded on Wednesday. The stock was one of the most active stocks on the NYSE. The company’s CEO has acknowledged that a potential merger with AstraZeneca would result in some job losses but he also has said that drugs development would “if anything” be accelerated if his company took over AstraZeneca.

SodaStream International Ltd. (NASDAQ: SODA) - For an in-depth report on SodaStream International Ltd. follow: www.BullTrends.com/stockquote/SODA

Shares of SODA closed down 1.22% on about 3.8 million shares traded on Wednesday. The stock was one of the most active stocks on the NASDAQ. For the three-month period ended March 31, the company posted a profit of $0.08 per diluted share, which was down from earnings per share of $0.57 during the same period a year ago. $0.08 in the latest quarter was better than the $0.01 profit that analysts were expecting.

Deere & Company (NYSE: DE) - For an in-depth report on Deere & Company follow: www.BullTrends.com/stockquote/DE

Deere & Company shares closed down 2.04% on about 5.3 million shares traded on Wednesday. The company reported a stronger-than-expected quarterly profit but also trimmed its outlook for full-year sales of farm equipment, citing deteriorating conditions in South America and the former Soviet Union.

Night Culture, Inc. (OTCBB: NGHT) - For an in-depth report on Night Culture, Inc. follow:  www.BullTrends.com/stockquote/NGHT

Shares of Night Culture Inc. closed down 24.82% on about 2.3 million shares traded. The stock was one of the biggest decliners in the OTCBB market. The company announced operating results for the quarter ending March 31, 2014, including a 24.4% increase in revenues to $1,264,685 in Q1 2014 compared to $1,016,986 during the same period in 2013.

 

Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures. 

Topic:
Back to newsroom
Back to Newsroom
Share by: